An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01240421
Expanded Access Status : Approved for marketing
First Posted : November 15, 2010
Last Update Posted : May 22, 2015
Information provided by (Responsible Party):
Eisai Inc.

No Study Results Posted on for this Study
  Expanded Access Status : Approved for marketing
  Estimated Primary Completion Date : March 2015
  Estimated Study Completion Date : November 2014